EF Hutton has begun coverage on UroGen Pharma (NASDAQ: URGN), assigning the stock a Buy rating and setting a price target of $25.00.
The firm's analysis suggests that UroGen Pharma is on the verge of significant growth, fueled by its expansion into the broader Cancer-Urology market with its new products, UGN102 and UGN103.
The company, which has been focusing on treatments for low-grade upper tract urothelial cancer with its product Jelmyto, is now setting its sights on addressing low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
The potential market for LG-IR-NMIBC is substantially larger, with an estimated 60,000 patients compared to the 7,000 patients with the condition that Jelmyto targets.
EF Hutton's optimistic outlook is based on UroGen Pharma's strategic move to cater to a broader patient population, which represents a significant increase in the addressable market. The analyst believes that this expansion could be a pivotal moment for the company, leading to a breakout in its stock performance.
UroGen Pharma's progress will be closely monitored by investors as the company continues to develop and market its treatments for various forms of cancer within the urology field. The EF Hutton coverage initiation marks an important moment for the company as it seeks to establish itself in a larger market with a substantial need for effective treatments.
In other recent news, UroGen Pharma has seen a reshuffling of its executive leadership, with Don Kim stepping down from his position as CFO and taking on a consulting role. Christopher Degnan has been appointed as the new CFO, bringing with him a wealth of experience from previous roles at Galera Therapeutics (OTC:GRTX) and Verrica Pharmaceuticals (NASDAQ:VRCA), among others.
This executive change comes as UroGen Pharma reports a 16% sequential increase and a 3% year-on-year growth in net product revenue for JELMYTO, amounting to $21.8 million. The company has also successfully completed its New Drug Application for UGN-102, a treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, and expects potential FDA approval in early 2025.
Moreover, the company secured a $25 million loan and raised approximately $116.2 million in a public offering to support the launch of UGN-102. UroGen Pharma also obtained a US patent for its RTGel® technology combined with a mitomycin formulation, expected to last until December 2041.
In terms of analyst feedback, both H.C. Wainwright and Oppenheimer have maintained their positive ratings for UroGen Pharma, citing these recent developments. Lastly, board member Fred E. Cohen, M.D., D.Phil., has resigned from his position, marking another significant change in the company's leadership.
InvestingPro Insights
To complement EF Hutton's bullish outlook on UroGen Pharma (NASDAQ: URGN), recent data from InvestingPro provides additional context for investors. The company's market capitalization stands at $530.64 million, reflecting its current position in the biotech sector. Despite the optimistic price target set by EF Hutton, it's important to note that UroGen is not currently profitable, with a negative P/E ratio of -4.69 over the last twelve months as of Q2 2024.
However, aligning with the growth narrative, UroGen has demonstrated revenue growth of 17.22% over the same period, reaching $85.01 million. This growth trajectory supports EF Hutton's thesis on the company's expansion potential. Moreover, UroGen boasts impressive gross profit margins of 89.87%, which is particularly noteworthy for a company in the development stage of novel cancer treatments.
InvestingPro Tips highlight that UroGen "holds more cash than debt on its balance sheet" and has "liquid assets exceed[ing] short term obligations," which could provide the financial flexibility needed to support its expansion into the broader Cancer-Urology market. However, investors should be aware that the company is "quickly burning through cash," a common characteristic of biotech firms investing heavily in R&D and market expansion.
For those seeking a deeper analysis, InvestingPro offers 8 additional tips for UroGen Pharma, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.